Reportstack

Antidepressant Market in the US 2015-2019

 

Naperville, IL -- (SBWIRE) -- 02/02/2015 -- Reportstack, provider of premium market research reports announces the addition of Antidepressant Market in the US 2015-2019 market report to its offering

About Depression
According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Depression can be recurrent, and can be severely debilitating for an individual. In patients with mild depression, the patient can be treated with medications, and in moderate or severe depression, a patient needs both medication and professional psychotherapy in terms of counseling. It has been reported by the WHO in 2008, that depression equally affects men and women, but women have a 50 percent higher tendency to get affected by depression than men. According to the CDC, depression can lead to adverse behavioral traits in an individual such as, alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, one out of every 10 people is affected with depression in the US. Major depressive disorder is among the most debilitating disorders in the US, and affects approximately 14.8 million adults in the country, aged 18 years and above, according to the NIMH in the US.

Analysts forecast the Antidepressant market in the US to grow at a CAGR of [4.08] percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Antidepressant market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of depression. The Antidepressant market in the US is segmented based on the mechanism of action of the drugs used to treat depression, as illustrated below:

Tricyclic Antidepressants
Serotonin Norepinephrine Reuptake Inhibitors
Selective Serotonin Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Others

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Antidepressant market in the US. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Antidepressant Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Antidepressant market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

Actavis
Eli Lilly and Company
GlaxoSmithKline
Otsuka Pharmaceutical
Pfizer

Other Prominent Vendors

Abbott Laboratories
AstraZeneca
Aurobindo Pharma
Bristol-Myers Squibb
Dr. Reddy's Laboratories
H. Lundbeck
Janssen Pharmaceuticals
Lupin
Novartis
Pierre Fabre
Shire
Somerset Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Valeant Pharmaceuticals

Market Driver

Rise in Patient Population
For a full, detailed list, view our report

Market Challenge

Threat from Patent Expiries
For a full, detailed list, view our report

Market Trend

Growing Public Awareness
For a full, detailed list, view our report

Key Questions Answered in this Report

What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Companies Mentioned
Actavis , Eli Lilly and Company, GlaxoSmithKline , Otsuka Pharmaceutical , Pfizer , Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Bristol-Myers Squibb, Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin, Novartis, Pierre Fabre , Shire , SomersetPharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals

Complete report is available
http://www.reportstack.com/product/191326/antidepressant-market-in-the-us-2015-2019.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604